Angle says Parsortix system could replace cancer tissue biopsy
Angle says Parsortix system could replace cancer tissue biopsy
Read moreAngle says Parsortix system could replace cancer tissue biopsy
Read moreAngle cancer study delayed as accreditation process for labs starts
Read moreTRADING UPDATES: Harvest Minerals sales jump; Quartix earnings to rise
Read moreEXECUTIVE CHANGES: Halma hires non-exec; Diurnal names new chair
Read moreAngle first-half loss widens, crucial FDA decision expected this year
Read moreIN BRIEF: Angle notes studies supporting Parsortix system in cancer
Read moreUK earnings, trading statements calendar - next 7 days
Read moreIN BRIEF: Angle's Parsortix used in Spanish study to find cancer
Read moreIN BRIEF: Angle's Parsortix enables gene analysis in cancer study
Read moreTRADING UPDATES: Netcall wins new deal; Sareum raises GBP1 million
Read moreTRADING UPDATES: United Oil & Gas in North Sea sale; Trifast confident
Read more(Sharecast News) - Liquid biopsy company Angle has agreed a pharma services contract with another new customer, it announced on Wednesday, for its recently-established pharma services business.
Read moreIN BRIEF: Angle's Parsortix successfully used to harvest cancer cells
Read moreIN BRIEF: Angle raises GBP20.0 million to fund FDA approval drive
Read moreIN BRIEF: Angle to raise GBP20 million through shares placing
Read more